Yousef Zakharia, MD | Authors

November 06, 2022

Yousef Zakharia, MD, discussed standard first-line treatment for renal cell carcinaoma.

May 15, 2021

Yousef Zakharia, MD, discusses the results of a phase 2 trial investigating concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.

May 28, 2020

Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.

May 16, 2020

Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.

May 11, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses indoximod as an active IDO inhibitor in advanced melanoma.

April 06, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.